



9 October 2007

NEW CHIEF COMMERCIAL OFFICER FOR NORGINE

Norgine, the independent European specialty pharmaceutical company has announced the new role of Chief Commercial Officer, and appointed Kenneth Scrimgeour with effect from the 1st October 2007.

Mr. Scrimgeour joined Norgine in December 2004, as Vice-President of the UK Business Unit. Prior to that he worked for Schering-Plough in a variety of senior sales and marketing roles in Europe and the USA.

In his new role Mr. Scrimgeour will be responsible for all of Norgine's worldwide Sales and Marketing Business Units as well as Global Marketing.

Peter Martin, Norgine's Chief Operating Officer, commented:

"I am delighted to announce the creation of this new position, which is vital to Norgine's mission in continuing as Europe's leading gastro-intestinal specialty pharmaceutical company. I look forward to Ken's future success in continuing to build a genuine pan-European Sales and Marketing organisation, strong in all the major countries, and able to launch products with equal success across the European Union".

ENDS

Notes to editor

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a presence in all the major European markets. In 2006 Norgine's sales were €188 million, the 20th consecutive year of double-digit growth. The company employs over 1000 people, of whom 350 are in sales and marketing.

Norgine's current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. MOVICOL® for the treatment of chronic constipation and faecal impaction, MOVIPREP® a new generation bowel cleansing preparation, KLEAN-PREP® for bowel preparation prior to colonoscopy, and ORAMORPH® for the treatment of moderate to severe pain associated with cancer.

Norgine has an active Research and Development effort and currently has products at various stages of clinical development. Norgine has two manufacturing sites; Hengoed in the UK and Dreux, France.

Norgine's website is www.norgine.com

For further information, please contact:

Paul Pay, Vice-President, Business Development, Norgine

T: +44 (0)1895 453710

E: ppay@norgine.com

Louise Blakeborough, Chapter Five

T: +44 (0)1306 731800

E: lblakeborough@chapterfive.co.uk